Diabetes patients currently inject their insulin, of course. But India's Biocon sees opportunity in developing an oral insulin pill, despite a late-stage clinical trial setback this year for its IN-105 oral insulin treatment. Biocon is in advance discussions with potential partners to continue the pill's development, Reuters is reporting, with potential tweaks in design of the trial protocol. Rumored potential partners include Novo Nordisk ($NVO) and Eli Lilly ($LLY). Story